Warren Hirst Selected Research

2- fluoro- 6- (tetrahydrofuran- 3- ylamino)- 4- (3,6,6- trimethyl- 4- oxo- 4,5,6,7- tetrahydro- 1H- indol- 1- yl)benzamide

1/2014

Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Warren Hirst Research Topics

Disease

1	Parkinson Disease (Parkinson's Disease) 01/2020
1	Weight Loss (Weight Reduction) 01/2014
1	Parkinsonian Disorders (Parkinsonism) 01/2014
1	Hypoxia (Hypoxemia) 03/2004

Drug/Important Bio-Agent (IBA)

1	Phosphotransferases (Kinase)IBA 01/2020
1	Leucine (L-Leucine)FDA Link 01/2020
1	SynucleinsIBA 01/2014
1	2- fluoro- 6- (tetrahydrofuran- 3- ylamino)- 4- (3,6,6- trimethyl- 4- oxo- 4,5,6,7- tetrahydro- 1H- indol- 1- yl)benzamideIBA 01/2014
1	Dopamine (Intropin)FDA LinkGeneric 01/2014
1	acadesineIBA 03/2004